The U.S. stock market has recently experienced a positive shift, with major indexes such as the Dow Jones and S&P 500 on track for their best week since June, following a brief trading halt due to technical issues. In this context of market recovery and optimism, investors may find value in exploring penny stocks—an investment area that still holds potential despite its somewhat outdated terminology. By focusing on smaller or newer companies with strong financial health, these stocks can offer opportunities for growth and stability.
Top 10 Penny Stocks In The United States
| Name | Share Price | Market Cap | Rewards & Risks |
| Dingdong (Cayman) (DDL) | $1.72 | $368.6M | ✅ 4 ⚠️ 0 View Analysis > |
| Waterdrop (WDH) | $1.76 | $636.53M | ✅ 4 ⚠️ 0 View Analysis > |
| WM Technology (MAPS) | $0.842 | $144M | ✅ 4 ⚠️ 2 View Analysis > |
| LexinFintech Holdings (LX) | $3.30 | $555.27M | ✅ 4 ⚠️ 2 View Analysis > |
| Tuya (TUYA) | $2.21 | $1.33B | ✅ 5 ⚠️ 1 View Analysis > |
| CI&T (CINT) | $4.49 | $582.88M | ✅ 5 ⚠️ 0 View Analysis > |
| Golden Growers Cooperative (GGRO.U) | $5.00 | $77.45M | ✅ 1 ⚠️ 5 View Analysis > |
| Cricut (CRCT) | $4.75 | $1.01B | ✅ 2 ⚠️ 2 View Analysis > |
| BAB (BABB) | $0.837 | $6.08M | ✅ 2 ⚠️ 3 View Analysis > |
| Lifetime Brands (LCUT) | $3.51 | $79.52M | ✅ 3 ⚠️ 2 View Analysis > |
Click here to see the full list of 349 stocks from our US Penny Stocks screener.
Below we spotlight a couple of our favorites from our exclusive screener.
Acumen Pharmaceuticals (ABOS)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Acumen Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer's disease, with a market cap of approximately $118.12 million.
Operations: Acumen Pharmaceuticals does not have any reported revenue segments at this time.
Market Cap: $118.12M
Acumen Pharmaceuticals is a pre-revenue clinical-stage biopharmaceutical company with a market cap of approximately US$118.12 million, focusing on Alzheimer's therapies. Despite its unprofitability and increased losses over the past five years, it maintains sufficient cash runway for over a year. The company's management and board are experienced, with recent additions like Dr. George Golumbeski enhancing strategic capabilities. Acumen's lead candidate, Sabirnetug (ACU193), is progressing in Phase 2 trials for early Alzheimer's disease, having received Fast Track designation from the FDA. The stock has shown high volatility recently and was dropped from the S&P Global BMI Index in September 2025.
- Unlock comprehensive insights into our analysis of Acumen Pharmaceuticals stock in this financial health report.
- Gain insights into Acumen Pharmaceuticals' outlook and expected performance with our report on the company's earnings estimates.
Blue Ridge Bankshares (BRBS)
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: Blue Ridge Bankshares, Inc. is a bank holding company for Blue Ridge Bank, National Association, offering commercial and consumer banking and financial services, with a market cap of $380.28 million.
Operations: The company's revenue is primarily generated through its commercial banking segment, which accounts for $96.79 million, complemented by $2.35 million from mortgage banking activities.
Market Cap: $380.28M
Blue Ridge Bankshares has shown a turnaround by becoming profitable in the last year, despite a historical decline in earnings. The company reported significant growth in net income for Q3 2025, reaching US$5.6 million from US$0.946 million the previous year, with improved earnings per share. Its financial stability is supported by low-risk funding sources and an appropriate loans-to-deposits ratio of 97%. Recent developments include completing a share buyback and declaring a special cash dividend of $0.25 per share. However, its board's short tenure suggests limited experience, which could impact strategic decisions moving forward.
- Navigate through the intricacies of Blue Ridge Bankshares with our comprehensive balance sheet health report here.
- Learn about Blue Ridge Bankshares' historical performance here.
Aftermath Silver (AAGF.F)
Simply Wall St Financial Health Rating: ★★★★☆☆
Overview: Aftermath Silver Ltd. is an exploration stage company focused on acquiring, exploring, and developing mineral properties in Chile and Peru, with a market cap of $174.50 million.
Operations: No revenue segments are reported for the company.
Market Cap: $174.5M
Aftermath Silver Ltd., a pre-revenue exploration company, recently completed the acquisition of the Berenguela project, benefiting from reduced payment obligations. Despite no significant revenue streams, its seasoned management and board bring valuable experience to navigate industry challenges. The company reported a net loss of CAD 2.92 million for Q1 2025, with losses increasing over five years at a rate of 15.9% annually. Although debt-free and with short-term assets exceeding liabilities, Aftermath faces volatility in share price and has less than one year of cash runway based on current free cash flow trends.
- Click to explore a detailed breakdown of our findings in Aftermath Silver's financial health report.
- Gain insights into Aftermath Silver's historical outcomes by reviewing our past performance report.
Turning Ideas Into Actions
- Embark on your investment journey to our 349 US Penny Stocks selection here.
- Interested In Other Possibilities? Trump's oil boom is here — pipelines are primed to profit. Discover the 22 US stocks riding the wave.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Valuation is complex, but we're here to simplify it.
Discover if Acumen Pharmaceuticals might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com